Evista package

Notice: Product images are for illustration purposes only and may differ from the medication you receive. Packaging and appearance may vary depending on the country of origin, and generic medications may be supplied by different manufacturers. The medication, strength, and active ingredients will match your prescription. At the Canadian Pharmacy Store we prioritize your health and safety by working with licensed pharmacy partners to provide safe, high-quality medications.

Evista (Raloxifene Hydrochloride)

Generic:Raloxifene

Evista

Raloxifene Hydrochloride

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:

Evista

Raloxifene Hydrochloride

Sourced from Mauritius Source: Mauritius
Prescription Required
Select product strength & quantity:
Select Strength & Quantity

Choose the strength, form, and package size that match your prescription.

Send Your Prescription

Upload your prescription online, request a transfer, or have your doctor fax us.

Pharmacist Review & Delivery

Reviewed by a licensed pharmacist and shipped to your U.S. address with tracking. Shipping details.

Description

Evista (raloxifene hydrochloride) is a bone health medications agent listed in our Bone health medications directory and prescribed for specified menopause-related symptoms, specified breast cancers, and specified bone disorders (1.1) (2.1). Administered via the oral route, Evista is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.

Evista is a medication containing the active pharmaceutical ingredient raloxifene hydrochloride, classified pharmacologically as a bone health medications agent (2.1). It is clinically indicated for the management of specified menopause-related symptoms, specified breast cancers, and specified bone disorders as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).

Within the Bone health medications section of our catalogue, patients and prescribers frequently review Evista alongside related therapies such as Raloxifene, Actonel (Risedronate Sodium), Alendronate Sodium, and Alfacalcidol.

Official Indications and Usage

® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. Important Limitations: Evista is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. (1.1)

Mechanism of Action and Pharmacology

Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism). The agonistic or antagonistic action of raloxifene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promoters. Raloxifene appears to act as an estrogen agonist in bone. (1.1)

What is Menopause?

Menopause marks the end of menstrual periods and can involve several symptoms. Hormonal and nonhormonal treatments have different purposes and risks. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Menopause condition guide for appointment questions and related therapies (2.1).

What is Breast cancer?

Breast cancer treatment depends on stage and tumor characteristics, including relevant receptors or biomarkers. Medicines are selected within an oncology plan. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Breast cancer condition guide for appointment questions and related therapies (2.1).

What is Osteoporosis?

Osteoporosis weakens bones and increases fracture risk. Treatment considers fracture history, bone measurements, and other health factors. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Osteoporosis condition guide for appointment questions and related therapies (2.1).

Ordering Evista from Canada for U.S. Delivery

U.S. patients can order Evista (Raloxifene) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.

Step 1

Send Your Prescription

Step 2

Pharmacist Safety Check

  • Multi-point dosing and interaction review completed in under 1 business day.
  • Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
  • Verified under our Pharmacy Safety Standards.
Step 3

$14.99 USD Tracked Parcel

  • Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
  • Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
  • Review full shipping and delivery details.
Step 4

U.S. Street Delivery & Payment

  • Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
  • You see and approve the country of origin upfront before your card is charged.
  • Report any delayed or damaged parcel within 48 hours for prompt resolution.

Fact Table

Clinical Specification Details
Brand / Product Name Evista
Chemical / Generic Name Raloxifene Hydrochloride
Pharmacological Class Bone health medications agent
Therapeutic Category Bone health medications
Molecular Weight 510.05. g/mol (2.1)
Bioavailability ~2% (1.1)
Elimination Half-Life ~27.7 hours (1.1)
Legal Status Rx-Only (Prescription Required)
Regulatory Reference Authorities U.S. FDA (DailyMed), Health Canada (DPD), NLM MedlinePlus
Routes of Administration Oral
Dosage Forms & Strengths 60 mg, white, elliptical, film-coated tablets (not scored) imprinted with 4165 on one side in edible blue ink. Tablets (not scored): 60 mg
Primary Indications Specified Menopause-Related Symptoms, Specified Breast Cancers, And Specified Bone Disorders
Pregnancy & Breastfeeding Consult Doctor / Prescriber before use
FDA UNII Identifier 4F86W47BR6
NLM RxNorm Concept ID (RxCUI) 1490065, 1490067
FDA Application License NDA020815
Official DailyMed SetID fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9
Catalogue Index Links Letter E Index · All Medications · All Categories

Directions

Dosage and Administration Overview

60 mg tablet orally once daily. 2.1 Recommended Dosing The recommended dosage is one 60 mg Evista (raloxifene hydrochloride tablets) tablet daily, which may be administered any time of day without regard to meals. For the indications in risk of invasive breast cancer the optimum duration of treatment is not known. (1.1)

Presentations and Strengths

60 mg, white, elliptical, film-coated tablets (not scored) imprinted with 4165 on one side in edible blue ink. Tablets (not scored): 60 mg. (1.1)

Administration Guidance

Take Evista orally at the same time(s) each day as directed on your prescription label (1.1). Check with your pharmacist whether your specific formulation should be taken with a meal or on an empty stomach, and swallow extended-release or film-coated tablets whole without crushing, chewing, or splitting unless the tablet is scored and your prescriber has instructed you to do so.

Missed Dose Guidance

If you miss a scheduled dose of Evista, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).

Ingredients

Active Pharmaceutical Ingredient

The active ingredient in Evista is raloxifene hydrochloride (2.1).

Excipients and Formulation Carriers

Film coatings, stabilizers, and inactive carriers vary by strength and manufacturer presentation. If you have a known allergy to lactose, dyes, sulfites, or specific preservatives, ask our pharmacist to check the exact excipient list for your selected package (2.1).

Cautions and important safety information

Boxed Warning

Warning: increased risk of venous thromboembolism and death from stroke Increased risk of deep vein thrombosis and pulmonary embolism have been reported with Evista. women with active or past history of venous thromboembolism should not take Evista. Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke. (1.1)

Contraindications

Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. Pregnancy. (1.1)

Key Clinical Precautions

Before starting or continuing Evista, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):

  • Heart failure: Fluid retention or cardiovascular workload changes may precipitate or worsen congestive heart failure in susceptible patients. Report sudden weight gain, shortness of breath, or ankle and leg swelling to your healthcare provider.
  • Cardiovascular events: Depending on the medication class and underlying medical history, patients should be monitored for signs of cardiovascular events such as chest pain, shortness of breath, sudden weakness, or slurred speech.
  • Fetal toxicity and pregnancy considerations: This medication may cause fetal harm when administered to a pregnant patient. Discuss pregnancy planning, effective contraception, and safe treatment alternatives with your healthcare provider.
  • Malignancy monitoring: Follow age-appropriate and treatment-specific screening recommendations discussed with your prescribing specialist.
  • Blood pressure elevation: Monitor blood pressure regularly during treatment and inform your clinician if sustained increases occur.

Pregnancy, Lactation, and Special Populations

Evista is contraindicated for use in pregnant women, and is not indicated for use in females of reproductive potential. Based on mechanism of action, Evista may block the important functions that estrogen has during all stages of pregnancy. Limited data with Evista use in pregnant women are insufficient to inform any drug associated risks for births defects or miscarriage. (1.1)

Interactions

Official Drug Interaction Overview

Cholestyramine: Use with Evista is not recommended. Reduces the absorption and enterohepatic cycling of raloxifene. Warfarin: Monitor prothrombin time when starting or stopping Evista. Highly Protein-Bound Drugs: Use with Evista with caution. Highly protein-bound drugs include diazepam, diazoxide, and lidocaine. (1.1)

Important Interaction Categories

Concomitant use of Evista with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):

  • Warfarin and vitamin K antagonists (such as Coumadin (Warfarin Sodium) or Warfarin Generic in our Cardiovascular directory): Concomitant administration may alter prothrombin time and International Normalized Ratio (INR) or have additive effects on hemostasis and bleeding risk. More frequent INR monitoring and clinical observation for bleeding are recommended.
  • Digoxin (such as Lanoxin (Digoxin) or Digoxin Generic): Co-administration can affect P-glycoprotein transport or renal clearance of digoxin, altering serum digoxin concentrations. Appropriate clinical and laboratory monitoring of digoxin levels is advised.
  • Antacids and multivalent cations (aluminum, magnesium, calcium, iron, or sucralfate in our Digestive health directory): Co-administration can chelate or alter gastric pH, reducing oral absorption. Ask your pharmacist whether doses should be separated by 2 to 4 hours.

Side effects

Like all medications, Evista can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):

  • Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; taking oral doses with food (when permitted by the label) may help.
  • Vomiting: Persistent vomiting that prevents fluid intake should be reported to your clinician to prevent dehydration.
  • Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
  • Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
  • Insomnia or sleep disturbances: Taking morning doses earlier in the day (if consistent with your prescription) may reduce nighttime restlessness.
  • Abdominal discomfort or stomach pain: Mild gastrointestinal upset may occur; report severe, persistent, or radiating abdominal pain promptly.

Clinical Trial and Postmarketing Adverse Reactions

Adverse reactions (>2% and more common than with placebo) include: hot flashes, leg cramps, peripheral edema, flu syndrome, arthralgia, sweating. Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to Evista in 8429 patients who were enrolled in placebo-controlled trials, including 6666 exposed for 1 year and 5685 for at least 3 years. Osteoporosis Treatment Clinical Trial (more), The safety of raloxifene in the treatment of osteoporosis was assessed in a large (7705 patients) multinational, placebo-controlled trial. (1.1)

When to Seek Immediate Medical Attention

Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).

Storage and handling

Handling Store at controlled room temperature, 20° to 25°C (68° to 77°F). The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses. (1.1)

Store Evista in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).

What is a generic drug?

A generic medication contains the exact same active pharmaceutical ingredient (raloxifene hydrochloride) as its brand-name counterpart and is formulated to deliver the same dosage strength, route of administration, safety profile, quality, and therapeutic performance (2.1). Regulatory authorities require generic manufacturers to demonstrate bioequivalence, meaning the generic medication releases its active ingredient into the bloodstream at virtually the same rate and to the same extent as the innovator brand.

While a generic tablet, capsule, or inhaler may differ in color, shape, scoring, or packaging due to trademark laws that govern brand appearance, its clinical mechanism and active ingredient match the reference medicine. Because generic manufacturers do not repeat the initial discovery and multi-phase clinical trial investments of the original brand, generic equivalents offer substantial cost savings for patients paying out of pocket.

Canadian Pharmacy Store delivers prescription and over-the-counter medications to U.S. residents. Browse our Bone health medications directory, explore all medications A-Z, review how ordering works and prescription requirements, or call 1-888-868-1920 for personal assistance matching your prescription.

Frequently Asked Questions About Evista

What is Evista and what active ingredient does it contain?

Evista is a bone health medications agent containing the active pharmaceutical ingredient raloxifene hydrochloride. It is supplied for oral administration and requires a valid prescription where applicable.

How does Evista work in the body?

Raloxifene is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism).

What conditions is Evista prescribed to treat?

Evista is primarily indicated for specified menopause-related symptoms, specified breast cancers, and specified bone disorders. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.

How should I take or use Evista?

Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Evista is administered via the oral route. Take it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.

What are the most common side effects of Evista?

Commonly reported side effects of Evista include feeling sick, vomiting, loose stools, headache, difficulty sleeping, and abdominal pain. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.

What medications or substances can interact with Evista?

Important interaction categories for Evista include warfarin, digoxin, and antacids. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.

Can Evista be used during pregnancy or breastfeeding?

Official prescribing information highlights pregnancy-related precautions for Evista. Inform your healthcare provider immediately if you are pregnant, planning to become pregnant, or breastfeeding so safe treatment options can be evaluated.

Do I need a prescription to buy Evista online from Canada?

Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Evista (Raloxifene) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).

Does Evista have a generic equivalent (Raloxifene) at a Canada pharmacy?

Yes. A lower-cost generic equivalent (Raloxifene) containing Raloxifene is available alongside brand-name Evista in our Canada pharmacy catalogue.

How is Evista shipped to U.S. residents, and how much does shipping cost?

Evista ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.

How can I send or transfer my Evista prescription, or ask about an unlisted strength?

You can upload a clear photo or PDF of your Evista prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.

References & Official Sources

Clinical, pharmacological, and safety facts for Evista (Raloxifene Hydrochloride) are compiled directly from official regulatory prescribing labels and primary biomedical databases:

  1. (1.1) Evista. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
  2. (2.1) MedlinePlus Medical Encyclopedia: Menopause. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
  3. (3.1) MedlinePlus Medical Encyclopedia: Breast Cancer. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
  4. (4.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).

Related Condition Guides

Related Guides

Call 1-888-868-1920Help